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A 34-year-old woman presented in July 2009 at our
institution with choroidal metastasis as first manifestation of
a non-small cell lung cancer. Symptoms of disease were a
progressive vision loss in the left eye and diplopia.
The ophthalmoscopy showed a big choroidal mass with
secondary subretinal fluid in the left eye; fluorescein angio-
grams, the optical coherence tomography (Figure 1A), and an
ultrasound retinal examination (Figure 2A) confirmed the
alteration of choroidal.
A total body computed tomography scan revealed a vo-
luminous mass in the upper right lung, small multiple bilateral
pulmonary nodules, and mediastinal lymphadenopathy.
Pathologic diagnosis of invasive papillary adenocarci-
noma was obtained from a transthoracic needle biopsy of the
upper right lung.
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FIGURE 1. The optical coherence tomography (OCT) gives an
optical image of the retina like a vertical section plane and mea-
sure the thickness of the retina. A, From top to bottom, the first
white arrow shows serous retinal detachment, the second one an
elevated retinal pigment epithelial layer, and the third one re-
vealed choroidal profile alteration. B, The white arrow showed res-
olution of subretinal fluid, no further mass-like lesion was detected,
and the retina and retinal pigment epithelial layer were flattened
with a normal profile of foveal depression.
FIGURE 2. A, Ultrasound retinal examination showed re-
flective masses that occupy the vitreous cavity. B, Ultrasound
retinal examination showed exudation disappearance and
almost complete mass flattening with normal profile of the
eyeball.
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She successively underwent three courses of systemic
chemotherapy with gemcitabine and cisplatin. In the same
period, the patient received two intraocular bevacizumab
(Avastin) administrations with a total dose of 1.25 mg. After
the intraocular treatment, a dimensional reduction of the
tumor mass has been detected both by ophthalmoscopy and
fluorescein angiograms. Moreover both the optical coherence
tomography (Figure 1B) and ultrasound retinal examination
showed exudation disappearance and almost complete mass
flattening (Figure 2B). Simultaneously, the patient obtained a
complete recovery from blurred vision while a systemic
stable disease has been detected by a total body computed
tomography. After the first three cycles, the patient received
six additional cycles of chemotherapy combined with sys-
temic bevacizumab and 12 additional maintenance doses of
bevacizumab every 2 weeks, without both relevant toxicity
and signs of disease progression. After 20 months of follow-
up, the eye status remained stable and no systemic progres-
sive disease was observed.
DISCUSSION
Treatment modalities for choroidal metastasis include
surgical enucleation, external beam radiotherapy, laser pho-
tocoagulation, and brachytherapy.1
Recent studies reported the efficacy of intravitreal be-
vacizumab for metastatic tumors.2–4 Moreover, a case of
complete and durable response of choroid metastasis from
non-small cell lung cancer with systemic bevacizumab and
chemotherapy has been also described.5
The intraocular administration of bevacizumab repre-
sents a newer effective and tolerable therapeutic option being
able to avoid visual loss and to ameliorate patient’s quality of
life. Further studies are warranted to confirm safety, efficacy,
and optimal treatment schedule of such treatment modality.
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